stockrow
Friday 6 November 2026
Export MEDP’s income statement to Excel — free account
Medpace Holdings, Inc.
MEDP Healthcare Diagnostics & Research
Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
- Revenue
- +8.50%
- EPS
- +24.6%
- Free cash flow
- −16.6%
Quarter to September 2026, against a year earlier
654.77
19.79
+3.12%
Follow MEDP
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
90.29 | 37.14 | 25.20 | 30.13 | 34.20 | 43.01 | 27.37 | 33.22 | 25.44 | 35.87 |
Piotroski F-Score |
7 | 5 | 9 | 7 | 7 | 7 | 8 | 9 | 7 | 8 |
Altman Z-Score |
2.65 | 2.33 | 3.90 | 5.52 | 6.30 | 8.00 | 5.24 | 6.53 | 6.51 | 8.04 |
P/S ratio |
3.04 | 3.33 | 2.67 | 3.50 | 5.36 | 6.83 | 4.62 | 4.98 | 4.88 | 6.40 |
P/FCF ratio |
16.39 | 16.93 | 13.39 | 16.40 | 21.82 | 33.20 | 19.21 | 23.66 | 17.97 | 23.76 |
Altman Z″-Score (non-manufacturers) |
1.83 | 0.80 | 1.66 | 2.62 | 2.68 | 3.21 | (1.34) | 0.15 | 1.89 | 0.20 |
Beneish M-Score |
(2.52) | (2.76) | (2.35) | (2.69) | (2.78) | (2.62) | (2.81) | (2.79) | (3.02) | (2.92) |
P/Operating CF |
44.10 | 50.63 | 47.70 | 52.97 | 47.02 | 110.09 | 49.35 | 60.03 | 53.94 | 84.10 |
P/B ratio |
2.10 | 2.88 | 3.19 | 4.15 | 6.16 | 8.19 | 17.46 | 16.80 | 12.46 | 35.29 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 316.26 | 51.19 | 31.32 | 0.00 | 0.00 | 79.86 | 0.00 |
EV/Sales |
3.41 | 3.83 | 2.81 | 3.43 | 5.13 | 6.49 | 4.67 | 4.91 | 4.61 | 6.25 |
EV/EBITDA |
12.69 | 16.20 | 14.91 | 19.59 | 25.58 | 33.75 | 22.67 | 25.48 | 20.43 | 28.09 |
EV/Operating CF |
15.66 | 17.17 | 12.64 | 14.62 | 18.38 | 28.16 | 17.58 | 21.35 | 15.98 | 22.17 |
EV/FCF |
18.37 | 19.52 | 14.08 | 16.04 | 20.91 | 31.55 | 19.43 | 23.33 | 17.00 | 23.19 |
Quick Ratio |
0.70 | 0.57 | 0.61 | 0.84 | 1.00 | 1.16 | 0.35 | 0.59 | 0.87 | 0.67 |
Current Ratio |
0.79 | 0.67 | 0.69 | 0.92 | 1.08 | 1.24 | 0.42 | 0.64 | 0.93 | 0.74 |
Net Debt/EBITDA |
1.37 | 2.15 | 0.62 | (0.80) | (1.41) | (2.03) | 0.07 | (0.68) | (1.41) | (0.88) |
Debt/Assets |
19.63% | 26.11% | 10.97% | 0.96% | 1.15% | 0.96% | 3.70% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.31 | 0.49 | 0.18 | 0.02 | 0.02 | 0.02 | 0.13 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.43 | 0.45 | 0.73 | 0.82 | 0.73 | 0.75 | 0.97 | 1.25 | 1.12 | 1.24 |
Operating CF/Net income |
6.83 | 2.49 | 2.15 | 2.02 | 1.78 | 1.45 | 1.58 | 1.53 | 1.51 | 1.58 |
Capex/Depreciation |
(0.22) | (0.32) | (0.51) | (0.77) | (1.67) | (1.34) | (1.65) | (1.39) | (1.25) | (1.11) |
Interest Coverage |
2.71 | 8.58 | 12.39 | 81.16 | (544.11) | 1,891.57 | 95.94 | 690.22 | (17.88) | (41.86) |
| 2.62% | 7.02% | 13.34% | 15.22% | 18.92% | 20.68% | 36.64% | 59.83% | 58.42% | 70.23% | |
| 1.37% | 4.05% | 7.60% | 9.49% | 11.44% | 11.92% | 16.29% | 18.80% | 21.52% | 22.13% | |
ROIC |
4.29% | 5.59% | 9.39% | 13.14% | 19.19% | 24.45% | 42.68% | 67.15% | 178.91% | 0.00% |
Return on Tangible Assets |
158.88% | (279.52%) | (273.45%) | 469.86% | 122.24% | 80.16% | (68.22%) | (134.22%) | 837.39% | (202.23%) |
Average Days of Receivables |
69.06 | 69.53 | 69.13 | 65.99 | 63.45 | 59.57 | 63.35 | 57.75 | 51.30 | 58.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
14.59% | 14.53% | 10.74% | 11.06% | 9.95% | 9.49% | 9.00% | 8.56% | 8.54% | 7.81% |
Intangible Assets out of Total Assets |
0.81 | 0.80 | 0.75 | 0.63 | 0.51 | 0.42 | 0.52 | 0.42 | 0.33 | 0.35 |
Share Based Compensation of Revenue |
2.33% | 1.02% | 0.92% | 2.41% | 1.49% | 1.27% | 1.47% | 1.09% | 1.21% | 1.37% |
Graham Net Nets |
(0.18) | (0.22) | (0.11) | (0.03) | (0.02) | 0.00 | (0.09) | (0.05) | (0.02) | (0.03) |
Graham Number |
12.37 | 17.03 | 28.00 | 35.65 | 45.50 | 55.00 | 45.20 | 61.37 | 88.52 | 74.88 |
Earnings Yield |
1.11% | 2.69% | 3.97% | 3.32% | 2.92% | 2.32% | 3.65% | 3.01% | 3.93% | 2.79% |
Free Cash Flow Yield |
6.10% | 5.91% | 7.47% | 6.10% | 4.58% | 3.01% | 5.21% | 4.23% | 5.56% | 4.21% |
Revenue per Share |
11.81 | 11.17 | 19.82 | 24.00 | 25.98 | 31.85 | 45.08 | 61.38 | 68.13 | 87.72 |
Operating CF per Share |
2.57 | 2.49 | 4.41 | 5.63 | 7.26 | 7.34 | 11.98 | 14.11 | 19.67 | 24.73 |
Capex per Share |
(0.38) | (0.31) | (0.45) | (0.50) | (0.88) | (0.79) | (1.14) | (1.19) | (1.18) | (1.09) |
Free Cash Flow per Share |
2.19 | 2.18 | 3.95 | 5.13 | 6.38 | 6.55 | 10.84 | 12.91 | 18.49 | 23.64 |
Cash per Share |
1.05 | 0.68 | 0.66 | 3.68 | 7.79 | 12.86 | 0.87 | 7.99 | 21.62 | 17.23 |
Shareholders Equity per Share |
17.11 | 12.89 | 16.59 | 20.24 | 22.61 | 26.57 | 11.93 | 18.19 | 26.67 | 15.91 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
17.11 | 12.89 | 16.59 | 20.24 | 22.61 | 26.57 | 11.93 | 18.19 | 26.67 | 15.91 |
Free Cash Flow |
78.20 | 85.09 | 140.56 | 183.96 | 227.34 | 235.06 | 351.17 | 396.73 | 572.27 | 681.87 |
Working Capital |
(35.35) | (62.73) | (78.91) | (25.97) | 33.54 | 133.70 | (469.51) | (331.30) | (75.32) | (354.12) |
Capital Expenditures |
(13.54) | (12.29) | (16.02) | (17.91) | (31.34) | (28.27) | (36.88) | (36.65) | (36.55) | (31.36) |
Net Current Asset Value |
(235.15) | (317.22) | (200.12) | (99.76) | (111.25) | (16.09) | (632.15) | (504.05) | (246.09) | (526.78) |
EV/EBIT |
27.37 | 25.78 | 19.58 | 23.19 | 28.46 | 37.34 | 24.48 | 27.47 | 21.77 | 29.56 |
Capex to Sales |
0.03 | 0.03 | 0.02 | 0.02 | 0.03 | 0.02 | 0.03 | 0.02 | 0.02 | 0.01 |
Price to Operating Income |
24.42 | 22.36 | 18.62 | 23.70 | 29.70 | 39.30 | 24.20 | 27.87 | 23.02 | 30.29 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.39 | 0.79 | 0.61 | 0.49 | 0.22 | 0.23 | 0.20 | 0.22 | 0.24 | 0.21 |
Cash ROIC |
9.31% | 10.93% | 19.54% | 21.16% | 20.68% | 16.43% | 75.58% | 49.32% | 38.28% | 71.32% |
Accounts Receivable Turnover |
5.82 | 5.36 | 6.51 | 5.96 | 5.85 | 6.58 | 6.64 | 6.84 | 7.09 | 7.24 |
Accounts Payable Turnover |
20.22 | 15.35 | 15.10 | 16.40 | 14.48 | 16.89 | 18.21 | 19.66 | 21.18 | 24.13 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
20.06 | 28.74 | 24.21 | 25.47 | 27.34 | 21.25 | 22.57 | 18.23 | 17.41 | 14.03 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
72.43 | 81.42 | 108.26 | 144.56 | 158.31 | 173.70 | 219.92 | 275.90 | 297.42 | 349.26 |
Average Payables |
9.82 | 13.79 | 16.71 | 19.57 | 24.48 | 26.12 | 29.37 | 32.47 | 32.20 | 30.34 |
Average Assets |
981.57 | 964.91 | 959.33 | 1,055.50 | 1,266.87 | 1,525.31 | 1,506.22 | 1,504.66 | 1,878.85 | 2,038.17 |
Average Common Equity |
512.09 | 557.12 | 546.62 | 657.99 | 766.03 | 879.35 | 669.66 | 472.67 | 692.25 | 642.31 |
Columns are period end dates · fundamentals updated 2 Nov 2026